LRRK2 in Parkinson's disease: Function in cells and neurodegeneration

FEBS Journal

Volumn 276, Issue 22, 2009, Pages 6436-6444

  Webber, Philip J ^a   West, Andrew B ^a  

^a NONE   (United States)

Author keywords

Dopaminergic cell death; Familial Parkinson's disease; GTPase; Leucine rich repeat kinase 2; MAP kinase; Neurodegeneration; Parkinsonism; Programmed cell death; Protein self assembly; Serine threonine protein kinase

Indexed keywords

LEUCINE RICH REPEAT KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHOTRANSFERASE;

CELL DEATH; ENZYME ACTIVATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MISSENSE MUTATION; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN FUNCTION; SHORT SURVEY;

ANIMALS; CELL DEATH; HUMANS; MODELS, BIOLOGICAL; MUTATION; PARKINSON DISEASE; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION;

EID: 70350450693     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/j.1742-4658.2009.07342.x     Document Type: Short Survey

References (59)

1. Biskup S West AB (2008). Zeroing in on LRRK2-linked pathogenic mechanisms in Parkinson's disease. Biochim Biophys Acta 1792, 625 633.
2. Healy DG, Falchi M, O'Sullivan SS, Bonifati V, Durr A, Bressman S, Brice A, Aasly J, Zabetian CP, Goldwurm S et al. (2008) Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol 7, 583 590.
3. Sen S West AB (2009). The therapeutic potential of LRRK2 and alpha-synuclein in Parkinson's disease. Antioxid Redox Signal 11, 2167 2187.
4. Kumari U Tan EK (2009) LRRK2 in Parkinson's disease: genetic and clinical studies from patients. FEBS J 276, doi :.
5. Anand VS Braithwaite SP (2009) LRRK2 in Parkinson's disease: biochemical functions. FEBS J 276, doi :.
6. Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, Jones CM, Marshall CJ, Springer CJ, Barford D et al. (2004) Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116, 855 867.
7. West AB, Moore DJ, Choi C, Andrabi SA, Li X, Dikeman D, Biskup S, Zhang Z, Lim KL, Dawson VL et al. (2007) Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum Mol Genet 16, 223 232.
8. Korr D, Toschi L, Donner P, Pohlenz HD, Kreft B Weiss B (2006) LRRK1 protein kinase activity is stimulated upon binding of GTP to its Roc domain. Cell Signal 18, 910 920.
9. van Egmond WN, Kortholt A, Plak K, Bosgraaf L, Bosgraaf S, Keizer-Gunnink I van Haastert PJ (2008) Intramolecular activation mechanism of the Dictyostelium LRRK2 homolog Roco protein GbpC. J Biol Chem 283, 30412 30420.
10. Westerlund M, Belin AC, Anvret A, Bickford P, Olson L Galter D (2008) Developmental regulation of leucine-rich repeat kinase 1 and 2 expression in the brain and other rodent and human organs: implications for Parkinson's disease. Neuroscience 152, 429 436.
11. Biskup S, Moore DJ, Rea A, Lorenz-Deperieux B, Coombes CE, Dawson VL, Dawson TM West AB (2007) Dynamic and redundant regulation of LRRK2 and LRRK1 expression. BMC Neurosci 8, 102.
12. Biskup S, Moore DJ, Celsi F, Higashi S, West AB, Andrabi SA, Kurkinen K, Yu SW, Savitt JM, Waldvogel HJ et al. (2006) Localization of LRRK2 to membranous and vesicular structures in mammalian brain. Ann Neurol 60, 557 569.
13. Gloeckner CJ, Kinkl N, Schumacher A, Braun RJ, O'Neill E, Meitinger T, Kolch W, Prokisch H Ueffing M (2006) The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. Hum Mol Genet 15, 223 232.
14. Hatano T, Kubo S, Imai S, Maeda M, Ishikawa K, Mizuno Y Hattori N (2007) Leucine-rich repeat kinase 2 associates with lipid rafts. Hum Mol Genet 16, 678 690.
15. West AB, Moore DJ, Biskup S, Bugayenko A, Smith WW, Ross CA, Dawson VL Dawson TM (2005) Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci USA 102, 16842 16847.
16. Li YH, Wang YY, Zhong S, Rong ZL, Ren YM, Li ZY, Zhang SP, Chang ZJ Liu L (2009) Transmembrane helix of novel oncogene with kinase-domain (NOK) influences its oligomerization and limits the activation of RAS/MAPK signaling. Mol Cells 27, 39 45.
17. Rosenberg OS, Deindl S, Comolli LR, Hoelz A, Downing KH, Nairn AC Kuriyan J (2006) Oligomerization states of the association domain and the holoenyzme of Ca2+/CaM kinase II. FEBS J 273, 682 694.
18. Sheth PR Watowich SJ (2005) Oligomerization-induced differential dephosphorylation of c-Met receptor tyrosine kinase. Biochemistry 44, 10984 10993.
19. Pelech S (2006) Dimerization in protein kinase signaling. J Biol 5, 12.
20. Leung IW Lassam N (1998) Dimerization via tandem leucine zippers is essential for the activation of the mitogen-activated protein kinase kinase kinase, MLK-3. J Biol Chem 273, 32408 32415.
21. Terai K Matsuda M (2006) The amino-terminal B-Raf-specific region mediates calcium-dependent homo- and hetero-dimerization of Raf. EMBO J 25, 3556 3564.
22. Deng J, Lewis PA, Greggio E, Sluch E, Beilina A Cookson MR (2008) Structure of the ROC domain from the Parkinson's disease-associated leucine-rich repeat kinase 2 reveals a dimeric GTPase. Proc Natl Acad Sci USA 105, 1499 1504.
23. Greggio E, Taymans JM, Zhen EY, Ryder J, Vancraenenbroeck R, Beilina A, Sun P, Deng J, Jaffe H, Baekelandt V et al. (2008) The Parkinson disease-associated leucine-rich repeat kinase 2 (LRRK2) is a dimer that undergoes intramolecular autophosphorylation. J Biol Chem 283, 16906 16914.
24. Manning G, Whyte DB, Martinez R, Hunter T Sudarsanam S (2002) The protein kinase complement of the human genome. Science 298, 1912 1934.
25. Maroney AC, Finn JP, Connors TJ, Durkin JT, Angeles T, Gessner G, Xu Z, Meyer SL, Savage MJ, Greene LA et al. (2001) Cep-1347 (KT7515), a semisynthetic inhibitor of the mixed lineage kinase family. J Biol Chem 276, 25302 25308.
26. Rana A, Gallo K, Godowski P, Hirai S, Ohno S, Zon L, Kyriakis JM Avruch J (1996) The mixed lineage kinase SPRK phosphorylates and activates the stress-activated protein kinase activator, SEK-1. J Biol Chem 271, 19025 19028.
27. Gloeckner CJ, Schumacher A, Boldt K Ueffing M (2009). The Parkinson disease-associated protein kinase LRRK2 exhibits MAPKKK activity and phosphorylates MKK3/6 and MKK4/7, in vitro. J Neurochem 109, 959 968.
28. Kolch W (2005) Coordinating ERK/MAPK signalling through scaffolds and inhibitors. Nat Rev Mol Cell Biol 6, 827 837.
29. Good M, Tang G, Singleton J, Remenyi A Lim WA (2009) The Ste5 scaffold directs mating signaling by catalytically unlocking the Fus3 MAP kinase for activation. Cell 136, 1085 1097.
30. White LR, Toft M, Kvam SN, Farrer MJ Aasly JO (2007) MAPK-pathway activity, Lrrk2 G2019S, and Parkinson's disease. J Neurosci Res 85, 1288 1294. (Pubitemid 46724372)
31. Olsen JV, Blagoev B, Gnad F, Macek B, Kumar C, Mortensen P Mann M (2006) Global, in vivo, and site-specific phosphorylation dynamics in signaling networks. Cell 127, 635 648.
32. Jaleel M, Nichols RJ, Deak M, Campbell DG, Gillardon F, Knebel A Alessi DR (2007) LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity. Biochem J 405, 307 317.
33. Oshiro N, Fukata Y Kaibuchi K (1998) Phosphorylation of moesin by rho-associated kinase (Rho-kinase) plays a crucial role in the formation of microvilli-like structures. J Biol Chem 273, 34663 34666.
34. Imai Y, Gehrke S, Wang HQ, Takahashi R, Hasegawa K, Oota E Lu B (2008) Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila. EMBO J 27, 2432 2443.
35. Loh SH, Francescut L, Lingor P, Bahr M Nicotera P (2008) Identification of new kinase clusters required for neurite outgrowth and retraction by a loss-of-function RNA interference screen. Cell Death Differ 15, 283 298.
36. Habig K, Walter M, Poths S, Riess O Bonin M (2008) RNA interference of LRRK2-microarray expression analysis of a Parkinson's disease key player. Neurogenetics 9, 83 94.
37. Higashi S, Biskup S, West AB, Trinkaus D, Dawson VL, Faull RL, Waldvogel HJ, Arai H, Dawson TM, Moore DJ et al. (2007) Localization of Parkinson's disease-associated LRRK2 in normal and pathological human brain. Brain Res 1155, 208 219. (Pubitemid 46900930)
38. MacLeod D, Dowman J, Hammond R, Leete T, Inoue K Abeliovich A (2006) The familial Parkinsonism gene LRRK2 regulates neurite process morphology. Neuron 52, 587 593.
39. Giasson BI, Covy JP, Bonini NM, Hurtig HI, Farrer MJ, Trojanowski JQ Van Deerlin VM (2006) Biochemical and pathological characterization of Lrrk2. Ann Neurol 59, 315 322.
40. Plowey ED, Cherra SJ 3rd., Liu YJ Chu CT (2008) Role of autophagy in G2019S-LRRK2-associated neurite shortening in differentiated SH-SY5Y cells. J Neurochem 105, 1048 1056.
41. Greggio E, Jain S, Kingsbury A, Bandopadhyay R, Lewis P, Kaganovich A, van der Brug MP, Beilina A, Blackinton J, Thomas KJ et al. (2006) Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol Dis 23, 329 341.
42. Smith WW, Pei Z, Jiang H, Dawson VL, Dawson TM Ross CA (2006) Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat Neurosci 9, 1231 1233.
43. Iaccarino C, Crosio C, Vitale C, Sanna G, Carri MT Barone P (2007) Apoptotic mechanisms in mutant LRRK2-mediated cell death. Hum Mol Genet 16, 1319 1326.
44. Ho CC, Rideout HJ, Ribe E, Troy CM Dauer WT (2009) The Parkinson disease protein leucine-rich repeat kinase 2 transduces death signals via Fas-associated protein with death domain and caspase-8 in a cellular model of neurodegeneration. J Neurosci 29, 1011 1016.
45. Li J Yuan J (2008) Caspases in apoptosis and beyond. Oncogene 27, 6194 6206.
46. Imtiyaz HZ, Zhou X, Zhang H, Chen D, Hu T Zhang J (2009) The death domain of FADD is essential for embryogenesis, lymphocyte development, and proliferation. J Biol Chem 284, 9917 9926.
47. Micheau O Tschopp J (2003) Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell 114, 181 190.
48. Li FY, Jeffrey PD, Yu JW Shi Y (2006) Crystal structure of a viral FLIP: insights into FLIP-mediated inhibition of death receptor signaling. J Biol Chem 281, 2960 2968.
49. Yu JW Shi Y (2008) FLIP and the death effector domain family. Oncogene 27, 6216 6227.
50. Shi Y 2002). Apoptosome: the cellular engine for the activation of caspase-9. Structure 10, 285 288.
51. Scaffidi C, Fulda S, Srinivasan A, Friesen C, Li F, Tomaselli KJ, Debatin KM, Krammer PH Peter ME (1998) Two CD95 (APO-1/Fas) signaling pathways. EMBO J 17, 1675 1687.
52. Ko HS, Bailey R, Smith WW, Liu Z, Shin JH, Lee YI, Zhang YJ, Jiang H, Ross CA, Moore DJ et al. (2009) CHIP regulates leucine-rich repeat kinase-2 ubiquitination, degradation, and toxicity. Proc Natl Acad Sci USA 106, 2897 2902.
53. Jiang J, Ballinger CA, Wu Y, Dai Q, Cyr DM, Hohfeld J Patterson C (2001) CHIP is a U-box-dependent E3 ubiquitin ligase: identification of Hsc70 as a target for ubiquitylation. J Biol Chem 276, 42938 42944.
54. Murata S, Minami Y, Minami M, Chiba T Tanaka K (2001) CHIP is a chaperone-dependent E3 ligase that ubiquitylates unfolded protein. EMBO Rep 2, 1133 1138.
55. Caplan AJ, Mandal AK Theodoraki MA (2007) Molecular chaperones and protein kinase quality control. Trends Cell Biol 17, 87 92.
56. Wang L, Xie C, Greggio E, Parisiadou L, Shim H, Sun L, Chandran J, Lin X, Lai C, Yang WJ et al. (2008) The chaperone activity of heat shock protein 90 is critical for maintaining the stability of leucine-rich repeat kinase 2. J Neurosci 28, 3384 3391.
57. Banerji U (2009) Heat shock protein 90 as a drug target: some like it hot. Clin Cancer Res 15, 9 14.
58. da Rocha Dias S, Friedlos F, Light Y, Springer C, Workman P Marais R (2005) Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin. Cancer Res 65, 10686 10691.
59. Grbovic OM, Basso AD, Sawai A, Ye Q, Friedlander P, Solit D Rosen N (2006) V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors. Proc Natl Acad Sci USA 103, 57 62.